Aurora Cannabis Inc. (ACB) shares surged by 6.2% to close at $6.17, driven by increased trading volume and positive industry sentiment due to potential U.S. regulatory easing. Expectations for quarterly earnings stand at $0.03 per share, with revenues projected to reach $63.79 million, up 7.3% from last year.

The optimism surrounding Aurora Cannabis is part of a broader trend in the cannabis industry, fueled by hopes of marijuana rescheduling and high-profile endorsements of CBD. While the stock currently holds a Zacks Rank #3 (Hold), investors are advised to monitor earnings estimate revisions for future performance.

In contrast, Bio-Rad Laboratories (BIO) saw a 4.1% decline in its stock price, closing at $296.52. The company is expected to report earnings of $2.25 per share, representing an 11.9% increase from the previous year. Bio-Rad also holds a Zacks Rank of #3 (Hold).

The AI industry is experiencing a second wave of growth, with lesser-known firms poised to deliver substantial profits in the future. Investors are encouraged to explore these opportunities beyond well-known stocks like Nvidia. Companies addressing major global challenges may offer significant returns in the months and years ahead.

Read more at Nasdaq: Aurora Cannabis (ACB) Soars 6.2%: Is Further Upside Left in the Stock?